CAMBRIDGE, MA – June 18, 2025 – HiFiBiO Therapeutics, a clinical stage immune modulation biotechnology company, announced its participation in the 2025 Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS), taking place June 24-27 in Boston, MA.
The company will present exciting preclinical data on three novel leading immunology programs: a bi-paratopic KLRG1 antibody HFB3024, an anti-PD-1 antibody HFB202501, and a BTLA agonist antibody HFB200604.
HiFiBiO’s novel immunotherapies and comprehensive translational platform demonstrate the company’s deep commitment to innovative research and the development of impactful therapies to address unmet medical needs.
Details of the poster presentation are as follows:
Title: A Novel Bi-paratopic KLRG1 Antibody Selectively Depletes Effector Memory CD8+ T Cells for Autoimmune Disease Treatment.
Session Date: Tuesday, 24 June 2025
Speaker: Juying Li, PhD, Head of Disease Biology
Title: HFB202501, a Novel Anti-PD-1 Antibody with Enhanced Effector Functions for Precision Depletion of Pathogenic T Cells in Autoimmune Diseases.
Session Date: Wednesday, 25 June 2025
Speaker: Roshan Kumar, PhD, Head of Research
Title: Application of HiFiBiO Drug Intelligence Science (DIS®) translational platform to guide the clinical development of HFB200604, a Phase I BTLA agonist monoclonal antibody.
Session Date: Thursday, 26 June 2025
Speaker: Juying Li, PhD, Head of Disease Biology
About HiFiBiO Therapeutics
HiFiBiO Therapeutics is a clinical-stage biotech driving a robust clinical pipeline of transformative immunotherapies targeting cancer and autoimmune diseases. HiFiBiO achieves an unprecedented understanding of immune modulation in human diseases by pioneering a unique high-resolution translational platform, Drug Intelligence Science (DIS®), which combines unique single-cell capabilities with AI/ML approaches. Using patient samples, DIS® enables the discovery of novel targets, effective antibody drugs, and predictive biomarkers to enhance the probability of success for immunotherapies. Moreover, HiFiBiO has established partnerships with major multinational pharmaceutical and biotech companies and has been recognized as one of the 2023 Fierce 15 biotech companies. For additional information, please visit www.hifibio.com
HiFiBiO® is a trademark of HiFiBiO Therapeutics and its affiliates